B
Bogdan Batko
Researcher at Jagiellonian University
Publications - 40
Citations - 677
Bogdan Batko is an academic researcher from Jagiellonian University. The author has contributed to research in topics: Rheumatoid arthritis & Medicine. The author has an hindex of 10, co-authored 31 publications receiving 357 citations.
Papers
More filters
Journal ArticleDOI
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Dinesh Khanna,Celia J. F. Lin,Daniel E. Furst,Jonathan G. Goldin,Grace Kim,Masataka Kuwana,Yannick Allanore,Marco Matucci-Cerinic,Oliver Distler,Yoshihito Shima,Jacob M van Laar,Helen Spotswood,Bridget Wagner,Jeffrey Siegel,Angelika Jahreis,Christopher P. Denton,Eleonora Lucero,Bernardo A. Pons-Estel,Mariano Rivero,Guillermo Tate,Vanessa Smith,Ellen De Langhe,Rasho Rashkov,Anastas Batalov,Ivan Goranov,Rumen Stoilov,James V. Dunne,Sindhu R. Johnson,Janet E. Pope,Dušanka Martinović Kaliterna,Mette Mogensen,Anne Braae Olesen,Joerg Henes,Ulf Müller-Ladner,Gabriela Riemekasten,Alla Skapenko,Panayiotis G. Vlachoyiannopoulos,Emese Kiss,Tünde Minier,Lorenzo Beretta,Elisa Gremese,Gabriele Valentini,Yoshihide Asano,Tatsuya Atsumi,Hironobu Ihn,Tomonori Ishii,Osamu Ishikawa,Hiroki Takahashi,Kazuhiko Takehara,Yoshiya Tanaka,Yoshioki Yamasaki,Loreta Bukauskiene,Irena Butrimiene,Gabriel Medrano Ramirez,Cesar Ramos-Remus,Tatiana Sofia Rodriguez Reyna,Jeska K de Vries-Bouwstra,Bogdan Batko,Sławomir Jeka,Eugeniusz J. Kucharz,Maria Majdan,Marzena Olesińska,Zaneta Smolenska,Jose Alves,Maria José Santos,C. Mihai,Simona Rednic,Ivan Castellvi Barranco,Francisco Javier Lopez Longo,Carmen Simeon Aznar,Patricia Carreira,Ulrich A. Walker,Emma Derrett-Smith,Bridget Griffiths,Neil McKay,Jacob Aelion,Michael S. Borofsky,Roy Fleischmann,Joseph Z. Forstot,Suzanne Kafaja,M. Faisal Khan,Michael D. Kohen,Richard J. Martin,Fabian Mendoza-Ballesteros,Alireza Nami,Shirley Pang,Grissel Rios,Robert W. Simms,Keith M. Sullivan,Virginia D. Steen +89 more
TL;DR: Findings for the secondary endpoint of FVC% predicted indicate that tocilizumab might preserve lung function in people with early SSc-ILD and elevated acute-phase reactants.
Journal ArticleDOI
Heterogeneity of peripheral blood monocytes, endothelial dysfunction and subclinical atherosclerosis in patients with systemic lupus erythematosus:
Tomasz Mikolajczyk,Grzegorz Osmenda,Bogdan Batko,Grzegorz Wilk,M Krezelok,Dominik Skiba,Tomasz Sliwa,Juliusz Pryjma,Tomasz J. Guzik,Tomasz J. Guzik +9 more
TL;DR: The observations suggest that CD14dimCD16+monocytes are associated with subclinical atherosclerosis in SLE, although the mechanism appears to be independent of endothelial dysfunction.
Journal ArticleDOI
Mechanisms of increased vascular superoxide production in human varicose veins.
Bartłomiej Guzik,Maciej Chwała,Paweł T. Matusik,Dominik Ludew,Dominik Skiba,Grzegorz Wilk,Wojciech Mrowiecki,Bogdan Batko,Andrzej Cencora,Bogusław Kapelak,Jerzy Sadowski,Ryszard Korbut,Tomasz J. Guzik +12 more
TL;DR: NADPH oxidases and NOS could represent valuable drug targets for pharmacological treatment and prevention of varicose vein disease and Oxidative stress may provide a link between endothelial dysfunction, inflammation, and immune activation and the development of chronic venous dysfunction.
Journal ArticleDOI
Prevalence and clinical characteristics of rheumatoid arthritis in Poland: a nationwide study.
Bogdan Batko,Stajszczyk M,Jerzy Świerkot,Karol Urbanski,Filip Raciborski,Mariusz Jędrzejewski,Piotr Wiland +6 more
TL;DR: This is the first cross-sectional population-based epidemiological study regarding prevalence of RA in the adult Polish population, and the results demonstrate a high prevalence, falling within the upper boundary estimates for Europe.
Journal ArticleDOI
Biosimilar switching - current state of knowledge.
Piotr Wiland,Bogdan Batko,Marek Brzosko,Eugeniusz J. Kucharz,Włodzimierz Samborski,Jerzy Świerkot,Ewa Więsik-Szewczyk,Julia Feldman +7 more
TL;DR: There is no clinical evidence that a single switch from an originator to a biosimilar medicine is associated with any significant risk for patient safety or reduction in therapeutic efficacy, according to the latest recommendations for the use of biosimilars in rheumatic diseases.